Engineering the airway regenerative niche: conditioning, biomaterials, and cell therapies for epithelial replacement

Airway epithelial cell transplantation offers a promising regenerative strategy for diseases such as cystic fibrosis, primary ciliary dyskinesia, and chronic rhinosinusitis, which are characterised by epithelial injury, mucus stasis, and persistent inflammation. Advances in the expansion and differentiation of airway basal cells have renewed optimism for clinical translation. However, therapeutic success remains limited by early graft loss, infection, and poor cell retention within the high-shear, mucus-rich airway environment. This review presents a unified translational framework that integrates airway conditioning, biomaterials, and epithelial cell therapy to address key barriers to engraftment. Conditioning is defined as a time-limited intervention that establishes a permissive “window of receptivity” by transiently reducing microbial burden, inflammation, oxidative stress, and fibrotic signalling during the critical early period following cell delivery. Biomaterial strategies, including clinically relevant hydrogels and extracellular matrix scaffolds, are discussed as approaches to improve epithelial coverage, enhance cell residence time, and enable localised delivery of adjunctive factors, while minimising luminal obstruction. We further describe how these components can be combined with autologous or induced pluripotent stem cell-derived airway basal cells to form an integrated therapeutic approach. This combination product spans both manufacturing and procedural domains, incorporating cells, matrices, conditioning regimens, and delivery techniques. We summarise preclinical and emerging clinical evidence supporting these approaches and examine key translational considerations, including safety, scalability, and regulatory expectations. By integrating biological, material, and clinical strategies, the framework presented in this review provides a pragmatic pathway toward durable airway epithelial regeneration and supports the development of first-in-human studies in the sinonasal and proximal airway.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-10-14
DOI
https://doi.org/10.1186/s12967-026-09087-w
Primary Topic
Tissue Engineering and Regenerative Medicine
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Engineering the airway regenerative niche: conditioning, biomaterials, and cell therapies for epithelial replacement

Katelin M. Allan, Kerry Watts, Shafagh A. Waters, Bradford A. Woodworth et al.
Journal of Translational Medicine
Tissue Engineering and Regenerative Medicine
article

Engineering the airway regenerative niche: conditioning, biomaterials, and cell therapies for epithelial replacement

Katelin M. Allan, Kerry Watts, Shafagh A. Waters, Bradford A. Woodworth, Do-Yeon Cho, Bradley S. Quon, Amin R. Javar, Catherine Banks, Philipp Kramer
article en

Abstract

Airway epithelial cell transplantation offers a promising regenerative strategy for diseases such as cystic fibrosis, primary ciliary dyskinesia, and chronic rhinosinusitis, which are characterised by epithelial injury, mucus stasis, and persistent inflammation. Advances in the expansion and differentiation of airway basal cells have renewed optimism for clinical translation. However, therapeutic success remains limited by early graft loss, infection, and poor cell retention within the high-shear, mucus-rich airway environment. This review presents a unified translational framework that integrates airway conditioning, biomaterials, and epithelial cell therapy to address key barriers to engraftment. Conditioning is defined as a time-limited intervention that establishes a permissive “window of receptivity” by transiently reducing microbial burden, inflammation, oxidative stress, and fibrotic signalling during the critical early period following cell delivery. Biomaterial strategies, including clinically relevant hydrogels and extracellular matrix scaffolds, are discussed as approaches to improve epithelial coverage, enhance cell residence time, and enable localised delivery of adjunctive factors, while minimising luminal obstruction. We further describe how these components can be combined with autologous or induced pluripotent stem cell-derived airway basal cells to form an integrated therapeutic approach. This combination product spans both manufacturing and procedural domains, incorporating cells, matrices, conditioning regimens, and delivery techniques. We summarise preclinical and emerging clinical evidence supporting these approaches and examine key translational considerations, including safety, scalability, and regulatory expectations. By integrating biological, material, and clinical strategies, the framework presented in this review provides a pragmatic pathway toward durable airway epithelial regeneration and supports the development of first-in-human studies in the sinonasal and proximal airway.

Journal of Translational Medicine
University of British Columbia (CA), St. Paul's Hospital (CA), Stemcell Technologies (CA), UNSW Sydney (AU), University of Alabama at Birmingham (US), Birmingham VA Medical Center (US), Sydney Children's Hospital (AU)
Good health and well-being
Openalex Percentile: Top 10%
Tissue Engineering and Regenerative Medicine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.